Pancreatic Cancer Research

ResearcherChangzhou No.2 People's HospitalNo recent work listed

Yue Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8410-678X; OpenAlex author ID A5100628057. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers

Papers 12

  1. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer. First author DOI 10.1002/mc.23627↗
  2. Insulin promotes the proliferation and migration of pancreatic cancer cells by up-regulating the expression of PLK1 through the PI3K/AKT pathway. Co-author DOI 10.1016/j.bbrc.2023.01.061↗
  3. LEM domain containing 1 promotes pancreatic cancer growth and metastasis by p53 and mTORC1 signaling pathway. Co-author DOI 10.1080/21655979.2022.2047404↗
  4. MUC4 is a novel mediator in H. pylori infection-related pancreatic cancer. Co-author DOI 10.3892/ol.2020.12384↗
  5. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway. Co-author DOI 10.1002/jcp.29181↗
  6. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway. Last author DOI 10.1002/mc.23011↗
  7. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. First author DOI 10.1186/s12876-018-0891-y↗
  8. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. Co-author DOI 10.1186/s13046-018-0807-2↗
  9. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗
  10. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Co-author DOI 10.3892/or.2017.6036↗
  11. The Expression and Prognostic Roles of MCMs in Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0164150↗
  12. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liming Tang · 4 shared papers, 2019–2022 · strength 0.54
  2. Qiuyang Chen · 5 shared papers, 2017–2023 · strength 0.54
  3. Xinchun Liu · 5 shared papers, 2016–2023 · strength 0.47
  4. Xiang Cao · 2 shared papers, 2022–2023 · strength 0.40
  5. Na Yao · 3 shared papers, 2019–2022 · strength 0.40
  6. Jishu Wei · 5 shared papers, 2016–2018 · strength 0.36
  7. Yi Miao · 5 shared papers, 2016–2018 · strength 0.35
  8. Yi Miao · 2 shared papers, 2017–2023 · strength 0.24
  9. Peng Wang · 2 shared papers, 2017–2023 · strength 0.24
  10. Kaichun Wu · 1 shared paper, 2023 · strength 0.24
  11. Chunzhao Yu · 1 shared paper, 2023 · strength 0.24
  12. Kuirong Jiang · 3 shared papers, 2017–2018 · strength 0.21
  13. Shangnan Dai · 1 shared paper, 2023 · strength 0.18
  14. Wentao Gao · 2 shared papers, 2017–2018 · strength 0.15
  15. Junli Wu · 2 shared papers, 2017–2018 · strength 0.15
  16. Yu Long Gong · 1 shared paper, 2021 · strength 0.14
  17. Yunpeng Peng · 2 shared papers, 2016–2017 · strength 0.11
  18. Jingjing Zhang · 2 shared papers, 2016–2017 · strength 0.11
  19. Chunfu Zhu · 1 shared paper, 2020 · strength 0.11
  20. Jun Yu · 1 shared paper, 2018 · strength 0.09
  21. Yun-Peng Peng · 1 shared paper, 2016 · strength 0.06
  22. Zipeng Lu · 1 shared paper, 2017 · strength 0.06
  23. Guodong Shi · 1 shared paper, 2017 · strength 0.06
  24. Yang Feng Wu · 1 shared paper, 2017 · strength 0.06
  25. Hao Yuan · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.